CN1694701A - 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂 - Google Patents

治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂 Download PDF

Info

Publication number
CN1694701A
CN1694701A CNA038250217A CN03825021A CN1694701A CN 1694701 A CN1694701 A CN 1694701A CN A038250217 A CNA038250217 A CN A038250217A CN 03825021 A CN03825021 A CN 03825021A CN 1694701 A CN1694701 A CN 1694701A
Authority
CN
China
Prior art keywords
nicotine
administration
rats
metabotropic glutamate
mpep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038250217A
Other languages
English (en)
Chinese (zh)
Inventor
A·马尔库
P·肯尼
N·佩特森
S·塞梅诺娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Scripps Research Institute
Original Assignee
Novartis AG
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Scripps Research Institute filed Critical Novartis AG
Publication of CN1694701A publication Critical patent/CN1694701A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA038250217A 2002-09-10 2003-09-10 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂 Pending CN1694701A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40986702P 2002-09-10 2002-09-10
US60/409,867 2002-09-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012102160928A Division CN102793698A (zh) 2002-09-10 2003-09-10 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂

Publications (1)

Publication Number Publication Date
CN1694701A true CN1694701A (zh) 2005-11-09

Family

ID=31994019

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA038250217A Pending CN1694701A (zh) 2002-09-10 2003-09-10 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂
CN2012102160928A Pending CN102793698A (zh) 2002-09-10 2003-09-10 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012102160928A Pending CN102793698A (zh) 2002-09-10 2003-09-10 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂

Country Status (10)

Country Link
US (2) US8354447B2 (cg-RX-API-DMAC7.html)
EP (1) EP1539149B1 (cg-RX-API-DMAC7.html)
JP (3) JP2006501265A (cg-RX-API-DMAC7.html)
CN (2) CN1694701A (cg-RX-API-DMAC7.html)
AT (1) ATE539768T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003270166A1 (cg-RX-API-DMAC7.html)
BR (1) BR0314192A (cg-RX-API-DMAC7.html)
CA (1) CA2498022C (cg-RX-API-DMAC7.html)
ES (1) ES2381664T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004024150A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151184A (zh) * 2019-04-19 2019-08-23 昆明依利科特科技有限公司 非接触式吸毒人员快速检测系统及方法
CN117597347A (zh) * 2021-05-13 2024-02-23 阿德克斯法尔马股份公司 作为mGlu7受体的负别构调节剂的稠合杂环衍生物

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
EP1578422B1 (en) 2002-12-20 2007-04-11 NicoNovum AB A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
BRPI0816970A2 (pt) 2007-09-14 2015-03-24 Ortho Mcneil Janssen Pharm 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US8685404B2 (en) 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2022123482A1 (en) * 2020-12-11 2022-06-16 Novartis Ag Use of mglur5 antagonists for treating amphetamine addiction
CN114088427A (zh) * 2021-11-22 2022-02-25 昆明理工大学 一种用于惯容器/悬架的性能测试试验台及试验方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200201023T2 (tr) * 1999-10-15 2002-09-23 F. Hoffmann-La Roche Ag Benzodiazepin türevleri.
GB0005700D0 (en) 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
US6916821B2 (en) * 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110151184A (zh) * 2019-04-19 2019-08-23 昆明依利科特科技有限公司 非接触式吸毒人员快速检测系统及方法
CN117597347A (zh) * 2021-05-13 2024-02-23 阿德克斯法尔马股份公司 作为mGlu7受体的负别构调节剂的稠合杂环衍生物

Also Published As

Publication number Publication date
WO2004024150A3 (en) 2004-08-19
AU2003270166A1 (en) 2004-04-30
US8354447B2 (en) 2013-01-15
BR0314192A (pt) 2005-07-26
AU2003270166A8 (en) 2004-04-30
ES2381664T3 (es) 2012-05-30
JP2006501265A (ja) 2006-01-12
WO2004024150A2 (en) 2004-03-25
CA2498022C (en) 2012-10-23
JP2010174039A (ja) 2010-08-12
CN102793698A (zh) 2012-11-28
US20060148835A1 (en) 2006-07-06
US20130210849A1 (en) 2013-08-15
EP1539149B1 (en) 2012-01-04
EP1539149A2 (en) 2005-06-15
JP2014074032A (ja) 2014-04-24
CA2498022A1 (en) 2004-03-25
ATE539768T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
CA2498022C (en) Combination of mglur antagonists for the treatment of addictive disorders
Branchek et al. Trace amine receptors as targets for novel therapeutics: legend, myth and fact
CN101065014A (zh) 通过诱导逆适应调节神经递质系统的方法
Hajós et al. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile
Preti New developments in the pharmacotherapy of cocaine abuse
De Bodinat et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
Entzeroth et al. Monoamine oxidase inhibitors-revisiting a therapeutic principle
Zomkowski et al. The role of the NMDA receptors and L-arginine–nitric oxide–cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test
CN1794981A (zh) 治疗抑郁症和其它情绪障碍的nmda受体拮抗剂和选择性5-羟色胺重摄取抑制剂的组合
CN1784221A (zh) 影响体重减轻的组合物
JP2010510314A (ja) 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法
Bosker et al. Future antidepressants: what is in the pipeline and what is missing?
Gardoni et al. Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia
Adell Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?
JP2020533296A (ja) 薬物誘発性ジスキネジアを治療するためのプリドピジン
Froestl et al. Cognitive enhancers (nootropics). Part 2: Drugs interacting with enzymes
Kelliny et al. Alzheimer's disease and frontotemporal dementia: a review of pathophysiology and therapeutic approaches
WO2008083442A1 (en) Method for formulating combination medications for adhd
Li et al. A review of the recent advances in the pharmacological management of Parkinson’s disease
H Rezvani et al. Novel medication targets for the treatment of alcoholism: preclinical studies
Somaini et al. Promising medications for cocaine dependence treatment
Mittur Piribedil: Antiparkinsonian properties and potential clinical utility in dopaminergic disorders
Money et al. Treating schizophrenia: novel targets for the cholinergic system
Kim et al. Antiallodynic effect of intrathecal Korean Red Ginseng in cisplatin-induced neuropathic pain rats
Pannu et al. Acetylcholine and depression: Scrutinizing future therapeutic targets for novel drug development

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20051109